
Unicycive Therapeutics, Inc.: updates and filings
Price
$3.35
November 20, 2026Market cap $98M
What Ploutos Investor adds for Unicycive Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 4 fiscal years, from 2022
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 16, 2026next Feb 12, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
September 2026
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Results of operationsForm8-K
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Sep 29, 2026Officer or director change, other material eventsForm8-K
- Sep 28, 2026Other material eventsForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 12, 2026Results of operationsForm8-K
- Aug 12, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 30, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 8, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 2, 2026Other material eventsForm8-K
- Jun 22, 2026Additional annual meeting materialFormDEFA14A
- Jun 22, 2026Shareholder voteForm8-K
- Jun 15, 2026FilingFormEFFECT
- Jun 11, 2026Correspondence with the SECFormCORRESP
- Jun 11, 2026Letter from the SECFormUPLOAD
- Jun 5, 2026Material agreement enteredForm8-K
- Jun 5, 2026Shelf registration for future offeringsFormS-3
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 12, 2026Results of operationsForm8-K
- May 12, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 6, 2026Shares registered for employeesFormS-8
- Apr 30, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | 8-K | Results of operations | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Sep 29, 2026 | 8-K | Officer or director change, other material events | Document |
| Sep 28, 2026 | 8-K | Other material events | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 12, 2026 | 8-K | Results of operations | Document |
| Aug 12, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 30, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 8, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 2, 2026 | 8-K | Other material events | Document |
| Jun 22, 2026 | DEFA14A | Additional annual meeting material | Document |
| Jun 22, 2026 | 8-K | Shareholder vote | Document |
| Jun 15, 2026 | EFFECT | Filing | Document |
| Jun 11, 2026 | CORRESP | Correspondence with the SEC | Document |
| Jun 11, 2026 | UPLOAD | Letter from the SEC | Document |
| Jun 5, 2026 | 8-K | Material agreement entered | Document |
| Jun 5, 2026 | S-3 | Shelf registration for future offerings | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 12, 2026 | 8-K | Results of operations | Document |
| May 12, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 6, 2026 | S-8 | Shares registered for employees | Document |
| Apr 30, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Mar 4, 2019.
The full analysis
What do Unicycive Therapeutics's filings show?
The filings are where every one of Unicycive Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.